Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy

Simple item page
dc.contributor.affiliation000000041762408X
dc.contributor.affiliationDepartment of Biochemistry and Molecular Biology, Universidad Complutense de Madrid, Facultad de Medicina, Madrid, Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; CSIC - Centro de Investigaciones Biológicas Margarita Salas (CIB), Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Madrid, Madrid, Spain; Department of Pharmaceutical Sciences, Faculdade de Farmácia da Universidade de Lisboa, Lisbon, Lisbon, Portugal; Faculdade de Farmácia da Universidade de Lisboa, Lisbon, Lisbon, Portugal; Faculdade de Medicina da Universidade de Lisboa, Lisbon, Lisbon, Portugal; IMDEA Nanociencia, Madrid, Madrid, Spain; CSIC - Centro Nacional de Biotecnologia (CNB), Madrid, Madrid, Spain; Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid, Madrid, Spainen
dc.contributor.authorGómez-Almería, M.
dc.contributor.authorMartínez-González, L.
dc.contributor.authorMatos, A.T.
dc.contributor.authorRodríguez-Cueto, C.
dc.contributor.authorVaz, A.R.
dc.contributor.authorMartín-Baquero, R.
dc.contributor.authorPérez de la Lastra, C.
dc.contributor.authorInfantes, R.
dc.contributor.authorFernández-Ruiz, J.
dc.contributor.authorPalomo, Valle
dc.contributor.authorGil, C.
dc.contributor.authorBrites, D.
dc.contributor.authorMartínez, A.
dc.contributor.authorDe Lago, E.
dc.date.accessioned2026-02-17T15:01:47Z
dc.date.available2026-02-17T15:01:47Z
dc.date.issued2026
dc.format.mimetypeapplication/pdfen
dc.identifier.doi10.1016/j.neuropharm.2025.110804
dc.identifier.urihttps://hdl.handle.net/20.500.12614/4163
dc.issue.number110804
dc.journal.titleNeuropharmacologyen
dc.language.isoenen
dc.relation.projectIDTEMPThis work was supported by La Caixa and Luz \u00F3n Foundations [grant number HR21-00931 ], the Instituto de Salud Carlos III [CIBERNED, grant numbers CB18/05/00040 and CB06/05/0089 ], MCINN ( PID2021-128906OB-100 ), and UID/04138/2025 ( https://doi.org/10.54499/UID/04138/2025 , iMed.ULisboa). VP acknowledges RYC2019-027489-I , funded by MCIN/AEI/10.13039/501100011033 and by El FSE invierte en tu futuro \u201D, PID2021-128340OA-I00 funded by MCIN/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR . CPL thanks MCIN/AEI/10.13039/501100011033 and FSE \u201Cinvierte en tu futuro \u201D for her predoctoral funding ( PRE2022-102282 ) within the project PID2021-128340OA-I00 .
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España
dc.rights.accessRightsopen accessen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.titleAssessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathyen
dc.typeresearch articleen
dc.type.hasVersionVoRen
dc.volume.number285

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S002839082500512X-main.pdf
Size:
5.19 MB
Format:
Adobe Portable Document Format
Download

Collections

Publications